"The Report Acute
Respiratory Distress Syndrome - Pipeline Review, H1 2017 provides
information on pricing, market analysis, shares, forecast, and
company profiles for key industry participants. -
MarketResearchReports.biz"
Summary
Global Markets Direct's latest
Pharmaceutical and Healthcare disease pipeline guide Acute
Respiratory Distress Syndrome Pipeline Review, H1 2017, provides an
overview of the Acute Respiratory Distress Syndrome (Respiratory)
pipeline landscape.
Acute respiratory distress
syndrome (ARDS) occurs when fluid fills up the air sacs in lungs.
This leads to low oxygen levels in the blood. Common causes of ARDS
include sepsis, inhalation of harmful substances, severe pneumonia
and head or chest injury. Signs and symptoms of ARDS include severe
shortness of breath, labored and unusually rapid breathing, low blood
pressure and confusion and extreme tiredness.
View Report @
http://www.marketresearchreports.biz/analysis/1021127
Report Highlights
Global Markets Direct's
Pharmaceutical and Healthcare latest pipeline guide Acute Respiratory
Distress Syndrome Pipeline Review, H1 2017, provides comprehensive
information on the therapeutics under development for Acute
Respiratory Distress Syndrome (Respiratory), complete with analysis
by stage of development, drug target, mechanism of action (MoA),
route of administration (RoA) and molecule type. The guide covers the
descriptive pharmacological action of the therapeutics, its complete
research and development history and latest news and press releases.
The Acute Respiratory Distress
Syndrome (Respiratory) pipeline guide also reviews of key players
involved in therapeutic development for Acute Respiratory Distress
Syndrome and features dormant and discontinued projects. The guide
covers therapeutics under Development by Companies /Universities
/Institutes, the molecules developed by Companies in Phase III, Phase
II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2,
4, 3, 2, 8 and 1 respectively. Similarly, the Universities portfolio
in Preclinical stages comprises 2 molecules, respectively.
Acute Respiratory Distress
Syndrome (Respiratory) pipeline guide helps in identifying and
tracking emerging players in the market and their portfolios,
enhances decision making capabilities and helps to create effective
counter strategies to gain competitive advantage. The guide is built
using data and information sourced from Global Markets Directs
proprietary databases, company/university websites, clinical trial
registries, conferences, SEC filings, investor presentations and
featured press releases from company/university sites and
industry-specific third party sources. Additionally, various dynamic
tracking processes ensure that the most recent developments are
captured on a real time basis.
Scope
- The pipeline guide provides a
snapshot of the global therapeutic landscape of Acute Respiratory
Distress Syndrome (Respiratory).
- The pipeline guide reviews
pipeline therapeutics for Acute Respiratory Distress Syndrome
(Respiratory) by companies and universities/research institutes based
on information derived from company and industry-specific sources.
- The pipeline guide covers
pipeline products based on several stages of development ranging from
pre-registration till discovery and undisclosed stages.
- The pipeline guide features
descriptive drug profiles for the pipeline products which comprise,
product description, descriptive licensing and collaboration details,
R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key
companies involved in Acute Respiratory Distress Syndrome
(Respiratory) therapeutics and enlists all their major and minor
projects.
- The pipeline guide evaluates
Acute Respiratory Distress Syndrome (Respiratory) therapeutics based
on mechanism of action (MoA), drug target, route of administration
(RoA) and molecule type.
- The pipeline guide encapsulates
all the dormant and discontinued pipeline projects.
- The pipeline guide reviews
latest news related to pipeline therapeutics for Acute Respiratory
Distress Syndrome (Respiratory)
Reasons to buy
- Procure strategically important
competitor information, analysis, and insights to formulate effective
R&D strategies.
- Recognize emerging players with
potentially strong product portfolio and create effective
counter-strategies to gain competitive advantage.
- Find and recognize significant
and varied types of therapeutics under development for Acute
Respiratory Distress Syndrome (Respiratory).
- Classify potential new clients
or partners in the target demographic.
- Develop tactical initiatives by
understanding the focus areas of leading companies.
- Plan mergers and acquisitions
meritoriously by identifying key players and its most promising
pipeline therapeutics.
- Formulate corrective measures
for pipeline projects by understanding Acute Respiratory Distress
Syndrome (Respiratory) pipeline depth and focus of Indication
therapeutics.
- Develop and design in-licensing
and out-licensing strategies by identifying prospective partners with
the most attractive projects to enhance and expand business potential
and scope.
- Adjust the therapeutic portfolio
by recognizing discontinued projects and understand from the know-how
what drove them from pipeline.
Table of Contents
List
of Tables
List
of Figures
Introduction
Global
Markets Direct Report Coverage
Acute
Respiratory Distress Syndrome - Overview
Acute
Respiratory Distress Syndrome - Therapeutics Development
Pipeline
Overview
Pipeline
by Companies
Pipeline
by Universities/Institutes
Products
under Development by Companies
Products
under Development by Universities/Institutes
Acute
Respiratory Distress Syndrome - Therapeutics Assessment
Assessment
by Target
Assessment
by Mechanism of Action
Assessment
by Route of Administration
Assessment
by Molecule Type
Acute
Respiratory Distress Syndrome - Companies Involved in Therapeutics
Development
Altor
BioScience Corp
Athersys
Inc
Commence
Bio Inc
Faron
Pharmaceuticals Oy
GlaxoSmithKline
Plc
Global
Blood Therapeutics Inc
Hydra
Biosciences Inc
Implicit
Bioscience Ltd
Phylogica
Ltd
Savara
Inc
Silence
Therapeutics Plc
Acute
Respiratory Distress Syndrome - Drug Profiles
ALT-836
- Drug Profile
Product
Description
Mechanism
Of Action
R&D
Progress
BIO-10901
- Drug Profile
Product
Description
Mechanism
Of Action
R&D
Progress
BIO-11006
- Drug Profile
About us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
Mr.
Nachiket
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
No comments:
Post a Comment